Roth Capital affirms Celldex Therapeutics (Nasdaq: CLDX) at Buy/Focus Pick with a price target of $43 after the company announced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE